Corbus Pharmaceuticals Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0.0 | $0.9 |
| Operating income | -$85.3 | -$48.7 | -$45.1 | -$39.8 | -$56.0 |
| Net income | -$78.5 | -$40.2 | -$44.6 | -$42.3 | -$45.6 |
| Balance Sheet | |||||
| Total debt | — | $0.0 | $15.9 | $18.8 | $18.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$64.5 | -$41.8 | -$36.1 | -$37.6 | -$48.2 |
Shares outstanding 18.5M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.